Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography

被引:26
|
作者
Mou, Tiantian [1 ]
Jing, Huihui [1 ]
Yang, Wenjiang [1 ]
Fang, Wei [2 ,3 ]
Peng, Cheng [4 ]
Guo, Feng [2 ,3 ]
Zhang, Xianzhong [1 ]
Pang, Yan [1 ]
Ma, Yunchuan [4 ]
机构
[1] Beijing Normal Univ, Coll Chem, Minist Educ, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
[2] Chinese Acad Med Sci, Cardiovasc Inst, Dept Nucl Med, Beijing 100037, Peoples R China
[3] Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
[4] Capital Med Univ, Xuan Wu Hosp, PET Ctr, Beijing 100053, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Positron emission tomography; Myocardial perfusion imaging; F-18]FP2OP; Mitochondria complex I; FLOW TRACER; KINETIC-ANALYSIS; PET; COMPLEX; EXPRESSION;
D O I
10.1016/j.bmc.2009.12.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myocardial extractions of pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[F-18]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([F-18]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)benzyloxy)ethoxy) ethyl ester (OTs-P2OP) and the nonradioactive 2-tert-butyl-5-[2-(2-[F-19]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([F-19]FP2OP) were synthesized and characterized by IR, H-1 NMR, C-13 NMR and MS analysis. By substituting tosyl of precursor OTs-P2OP with F-18, the radiolabeled complex [F-18]FP2OP was prepared and further evaluated for its in vitro physicochemical properties, in vivo biodistribution, the metabolic stability in mice, ex vivo autoradiography and cardiac PET/CT imaging. Results: Starting with [F-18]F Kryptofix 2.2.2./K2CO3 solution, the total reaction time for [F-18]FP2OP was about 100 min, with final high-performance liquid chromatography purification included. Typical decay-corrected radiochemical yield stayed at 41 +/- 5.3%, the radiochemical purity, 98% or more. Biodistribution in mice showed that the heart uptake of [F-18]FP2OP was 41.90 +/- 4.52% ID/g at 2 min post-injection time, when the ratio of heart/liver, heart/lung and heart/blood reached 6.83, 9.49 and 35.74, respectively. Lipophilic molecule was further produced by metabolized [F-18]FP2OP in blood and urine at 30 min. Ex vivo autoradiography demonstrates that [F-18]FP2OP may have high affinity with MC-I and that can be blocked by [F-19] FP2OP or rotenone (a known MC-I inhibitor). Cardiac PET images were obtained in a Chinese mini-swine at 5, 15, 30 and 60 min post-injection time with high quality. Conclusion: [F-18]FP2OP was synthesized with high radiochemical yield. The promising biological properties of [F-18]FP2OP suggest high potential as MPI agent for positron emission tomography in the future. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1312 / 1320
页数:9
相关论文
共 50 条
  • [31] Positron-Emission Tomography Imaging of the TSPO with [18F]FEPPA in a Preclinical Breast Cancer Model
    Vasdev, Neil
    Green, David E.
    Vines, Douglass C.
    McLarty, Kristin
    McCormick, Patrick N.
    Moran, Matthew D.
    Houle, Sylvain
    Wilson, Alan A.
    Reilly, Raymond M.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2013, 28 (03) : 254 - 259
  • [32] Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer
    Sun, HH
    Sloan, A
    Mangner, TJ
    Vaishampayan, U
    Muzik, O
    Collins, JM
    Douglas, K
    Shields, AF
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (01) : 15 - 22
  • [33] Labeling Strategies of Peptides with 18F for Positron Emission Tomography
    Olberg, D. E.
    Hjelstuen, O. K.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (16) : 1669 - 1679
  • [34] An improved synthesis of 1-[18F]fluoroethyl--d-lactose ([18F]-FEL) for positron emission tomography imaging of pancreatic cancer
    Turkman, Nashaat
    Gelovani, Juri G.
    Alauddin, Mian M.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 (07) : 351 - 355
  • [35] The role of [18F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors
    Kaira, Kyoichi
    Sunaga, Noriaki
    Ishizuka, Tamotsu
    Shimizu, Kimihiro
    Yamamoto, Nobuyuki
    CANCER IMAGING, 2011, 11 (01) : 195 - 201
  • [36] Radiosynthesis and evaluation of 18F-labeled aliphatic phosphonium cations as a myocardial imaging agent for positron emission tomography
    Kim, Dong-Yeon
    Kim, Hyeon Sik
    Min, Jung-Joon
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (07) : 747 - 754
  • [37] Comparison of Reconstruction Methods in a Small Animal Cardiac Positron Emission Tomography Study Using a 18F-Labeled Myocardial Agent, [18F] FPTP
    Kim, Hyeon-Sik
    Lee, Byeong-il
    Kim, Ju Han
    Bom, Hee-Seung
    Kim, Dong-Yeon
    Min, Jung-Joon
    IRANIAN JOURNAL OF RADIOLOGY, 2017, 14 (01)
  • [38] Synthesis of [18F]BODIPY: Bifunctional Reporter for Hybrid Optical/Positron Emission Tomography Imaging
    Hendricks, J. Adam
    Keliher, Edmund J.
    Wan, Dongpeng
    Hilderbrand, Scott A.
    Weissleder, Ralph
    Mazitschek, Ralph
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2012, 51 (19) : 4603 - 4606
  • [39] [18F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model
    Pottier, Geraldine
    Bernards, Nicholas
    Dolle, Frederic
    Boisgard, Raphael
    ARTHRITIS RESEARCH & THERAPY, 2014, 16 (02)
  • [40] Novel methodology for labelling mesoporous silica nanoparticles using the 18F isotope and their in vivo biodistribution by positron emission tomography
    Rojas, Santiago
    Domingo Gispert, Juan
    Menchon, Cristina
    Baldovi, Herme G.
    Buaki-Sogo, Mireia
    Rocha, Milagros
    Abad, Sergio
    Manuel Victor, Victor
    Garcia, Hermenegildo
    Raul Herance, Jose
    JOURNAL OF NANOPARTICLE RESEARCH, 2015, 17 (03)